Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Market for Generics to Expand to ¥359.7 Bil. in 2010
January 12, 2009
- Kyowa Kirin to Transfer Neu-Up to Avoid Problems with AML
January 12, 2009
- Korosho to Educate Doctors on Benefits of Generics
January 12, 2009
- MediciNova Proposes Acquisition to Avigen
January 12, 2009
- New Management Team Members Appointed for Ranbaxy
January 12, 2009
- MTPC Transfers Shares of API to MCC
January 12, 2009
- Business Strategy for 2009 Announced by Agilent Technologies
January 12, 2009
- Novartis, Mochida Terminate Copromotion of Diovan
January 12, 2009
- RDKK Launches Titanium Series of Reagent Kits for Its Genome Sequencer FLX
January 12, 2009
- Korosho Asks Insurers to Participate in Councils for Promotion of the Use of Generics
January 5, 2009
- R&D NEWS IN BRIEF
January 5, 2009
- Korosho to Provide ¥20 Bil. by Promoting Use of Generics
January 5, 2009
- JPhA to Demand Direct Talk with Korosho
January 5, 2009
- JHIA to Promote Use of Generics
January 5, 2009
- Etizolam, Loxoprofen Taken during Pregnancy Don't Increase Incidence of Malformations
January 5, 2009
- Global Sales of Generics Totaled US$78.0 Bil. in 2007
January 5, 2009
- Ciclosporin Is Useful Option for Patients Resistant to Steroids: Dr Igarashi
January 5, 2009
- Dissolution of Original and Generic UDCA Products to Be Studied by NIHS
January 5, 2009
- Infliximab Can Be Withdrawn for Over 1 Year in Majority of Patients: Prof. Tanaka
January 5, 2009
- Prasugrel Receives Positive Opinion from CHMP
January 5, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…